|Bid||0.2518 x 1000|
|Ask||0.2682 x 800|
|Day's Range||0.2500 - 0.2700|
|52 Week Range||0.1850 - 2.5200|
|Beta (5Y Monthly)||1.07|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Iterum Therapeutics PLC (ITRM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Iterum Therapeutics PLC (ITRM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.